KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments (2016 - 2018)

Travere Therapeutics (TVTX) has disclosed Short-term Investments for 6 consecutive years, with $166.4 million as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Short-term Investments fell 19.51% year-over-year to $166.4 million, compared with a TTM value of $166.4 million through Jun 2018, down 19.51%, and an annual FY2017 reading of $201.2 million, down 6.35% over the prior year.
  • Short-term Investments was $166.4 million for Q2 2018 at Travere Therapeutics, down from $202.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $250.4 million in Q3 2016 and bottomed at $5.9 million in Q2 2015.
  • Average Short-term Investments over 5 years is $148.3 million, with a median of $199.7 million recorded in 2016.
  • The sharpest move saw Short-term Investments soared 7085.29% in 2014, then decreased 19.51% in 2018.
  • Year by year, Short-term Investments stood at $9.6 million in 2014, then surged by 1907.11% to $191.8 million in 2015, then increased by 12.03% to $214.9 million in 2016, then decreased by 6.35% to $201.2 million in 2017, then decreased by 17.32% to $166.4 million in 2018.
  • Business Quant data shows Short-term Investments for TVTX at $166.4 million in Q2 2018, $202.9 million in Q1 2018, and $201.2 million in Q4 2017.